Literature DB >> 15310791

Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia.

U Creutzig, G J L Kaspers.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15310791     DOI： 10.1200/JCO.2004.99.116

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  19 in total

1.  Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR.

Authors:  X He; Q Wang; J Cen; H Qiu; A Sun; S Chen; D Wu
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

2.  Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.

Authors:  Yasmin M Abaza; Tapan M Kadia; Elias J Jabbour; Marina Y Konopleva; Gautam Borthakur; Alessandra Ferrajoli; Zeev Estrov; William G Wierda; Ana Alfonso; Toh Han Chong; Charles Chuah; Liang-Piu Koh; Boon-Cher Goh; Julie E Chang; Daniel E Durkes; Maria Cielo Foudray; Hagop M Kantarjian; Xiao Qin Dong; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2017-08-25       Impact factor: 6.860

3.  Prevalence and Prognostic Impact of CEBPA Gene Mutation (Simplified Assay Technique) in Egyptian Acute Myeloid Leukemia Patients with Normal Cytogenetics.

Authors:  Samy B Said; Samir A El-Masry; Dalia A Salem; Mona M Taalab; Amr S Al-Posttany
Journal:  Indian J Hematol Blood Transfus       Date:  2015-11-30       Impact factor: 0.900

4.  Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study.

Authors:  Eva A Coenen; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

5.  Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

Authors:  Hui Liu; Rong Fu; Lijuan Li; Guojin Wang; Jia Song; Erbao Ruan; Huaquan Wang; Yuhong Wu; Xiaoming Wang; Kai Ding; Zonghong Shao
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

6.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

7.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.

Authors:  Brian V Balgobind; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Rob Pieters; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2009-06-15       Impact factor: 22.113

8.  Efficacy of 10-day decitabine in acute myeloid leukemia.

Authors:  Ian M Bouligny; Vivek Mehta; Scott Isom; Leslie R Ellis; Rupali R Bhave; Dianna S Howard; Susan Lyerly; Megan Manuel; Sarah Dralle; Bayard L Powell; Timothy S Pardee
Journal:  Leuk Res       Date:  2021-02-12       Impact factor: 3.156

9.  Easily manageable prognostic factors in 152 Chinese elderly acute myeloid leukemia patients: a single-center retrospective study.

Authors:  Jiadai Xu; Tingmei Chen; Yun Liu; Huayuan Zhu; Wei Wu; WenYi Shen; Bei Xu; Sixuan Qian; Jianyong Li; Peng Liu
Journal:  J Biomed Res       Date:  2014-02-20

10.  Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.

Authors:  Yang Shen; Ya-Kai Fu; Yong-Mei Zhu; Yin-Jun Lou; Zhao-Hui Gu; Jing-Yi Shi; Bing Chen; Chao Chen; Hong-Hu Zhu; Jiong Hu; Wei-Li Zhao; Jian-Qing Mi; Li Chen; Hong-Ming Zhu; Zhi-Xiang Shen; Jie Jin; Zhen-Yi Wang; Jun-Min Li; Zhu Chen; Sai-Juan Chen
Journal:  EBioMedicine       Date:  2015-04-12       Impact factor: 8.143
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.